TuHURA Biosciences
HURA · Nasdaq · United States
Share price · HURA
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when HURA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 23 Oct 2026+8.5%
Nothing announced by HURA that day or the session before.
- 21 Oct 2026+18.5%
Nothing announced by HURA that day or the session before.
- 21 Aug 2026-9.9%
- 26 Jun 2026-16.6%
Nothing announced by HURA that day or the session before.
- 18 Jun 2026+15.8%
- 10 Feb 2026+60.5%
Nothing announced by HURA that day or the session before.
- 9 Feb 2026+28.8%
Nothing announced by HURA that day or the session before.
- 6 Feb 2026+43.0%
Nothing announced by HURA that day or the session before.
- 24 Dec 2025+15.2%
Nothing announced by HURA that day or the session before.
- 10 Dec 2025-12.0%
Share of unusual movement by asset
For each asset, the share of HURA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
| Other company news (earnings, financing, releases naming no asset) | — | 30% |
| Sessions with no dated event | — | 70% |
No dated announcements about its assets since 2 Jul 2024.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2/3 | Innate immune activation (intralesional plasmid DNA)Gene therapy / editing | Merkel Cell Carcinoma |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Financial reports
Quarterly & interim (17)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $3.7M | $1.9M | $6.4M-$5.0M operating cash flow | report ↗ |
View 16 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $6.6M | $1.0M | $9.2M-$8.6M operating cash flow | report ↗ |
| 2026-Q1 | $0 | $5.2M | $6.3M | $7.5M-$4.4M operating cash flow | report ↗ |
| 2025-Q3 | — | $5.0M | $2.7M | $7.1M-$11M operating cash flow | report ↗ |
| 2025-Q2 | — | $4.9M | $8.5M | $9.5M-$6.3M operating cash flow | report ↗ |
| 2025-Q1 | $0 | $4.6M | $6.2M | $6.7M-$4.7M operating cash flow | report ↗ |
| 2024-Q3 | — | $0.3M | $3.0M | $2.2M-$1.9M operating cash flow | report ↗ |
| 2024-Q2 | — | $2.8M | $4.9M | $5.3M-$1.4M operating cash flow | report ↗ |
| 2024-Q1 | $0 | $0.6M | $6.3M | $2.0M-$3.8M operating cash flow | report ↗ |
| 2023-Q4 | — | $0.1M | $0.7M | $1.0M-$2.1M operating cash flow | report ↗ |
| 2023-Q3 | — | $1.9M | $0.2M | $3.0M-$1.3M operating cash flow | report ↗ |
| 2023-Q1 | — | $2.0M | $3.0M | $3.3M-$1.8M operating cash flow | report ↗ |
| 2022-Q4 | — | $2.1M | $4.9M | $3.5M-$2.2M operating cash flow | report ↗ |
| 2022-Q3 | — | $3.2M | $7.1M | $4.6M-$6.4M operating cash flow | report ↗ |
| 2022-Q1 | — | $3.5M | $8.8M | $5.4M-$5.2M operating cash flow | report ↗ |
| 2021-Q4 | — | $3.9M | $14M | $5.9M-$5.1M operating cash flow | report ↗ |
| 2021-Q3 | — | $3.8M | $19M | $6.0M-$5.1M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $0 | $21M | $3.6M | $7.5M-$28M operating cash flow | report ↗ |
TuHURA Biosciences reported revenue of $0M for FY2025, with R&D spend of $20.53M. Cash and equivalents totaled $3.62M, while the company posted a net loss of $30.05M, corresponding to a quarterly net burn of $30.05M.
TuHURA is a Phase 3 clinical-stage immuno-oncology company focused on overcoming resistance to cancer immunotherapies. During the period, it initiated a Phase 3 registration trial of IFx-2.0 as an adjunctive therapy to pembrolizumab in first-line advanced or metastatic Merkel cell carcinoma, completed its acquisition of Kineta in June 2025, and gained rights to the VISTA-inhibiting antibody TBS-2025, with a planned Phase 1b/2 trial in relapsed/refractory mutated NPM1 AML. The company is also advancing DOR-targeting bi-specific ADC candidates in preclinical development.
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-17 | Bianco James A. · director, Chief Executive Officer | Gift | 75,000 | — | — | Form 4 |
| 2026-05-28 | Bianco James A. · director, Chief Executive Officer | Gift | 150,000 | — | — | Form 4 |
| 2026-02-12 | Hoffman Robert E. · director | Award / grant (derivative) | 156,240 | — | — | Form 4 |
| 2026-02-12 | List Alan · director | Award / grant (derivative) | 156,240 | — | — | Form 4 |
| 2026-02-12 | MANUSO JAMES S J · director | Award / grant (derivative) | 156,240 | — | — | Form 4 |
| 2026-02-12 | Ng George K · director | Award / grant (derivative) | 156,240 | — | — | Form 4 |
| 2026-02-12 | Tendler Craig · director | Award / grant (derivative) | 156,240 | — | — | Form 4 |
| 2026-01-06 | Bianco James A. · director, Chief Executive Officer | Award / grant (derivative) | 610,332 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 87 reporting institutions held 9.5M shares ($16.8M, 14.8% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 2,450,256 | $4.4M |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 2,074,228 | $3.7M |
| 3 | GEODE CAPITAL MANAGEMENT, LLC | 986,922 | $1.8M |
| 4 | AQR CAPITAL MANAGEMENT LLC | 607,168 | $1.1M |
| 5 | STATE STREET CORP | 512,913 | $918K |
| 6 | NORTHERN TRUST CORP | 298,187 | $534K |
| 7 | VANGUARD FIDUCIARY TRUST CO | 287,133 | $514K |
| 8 | VANGUARD PORTFOLIO MANAGEMENT LLC | 253,641 | $454K |
| 9 | Bank of New York Mellon Corp | 211,568 | $379K |
| 10 | Apollon Wealth Management, LLC | 158,010 | $283K |
| 11 | Cetera Investment Advisers | 140,244 | $251K |
| 12 | Suncoast Equity Management | 104,409 | $187K |
| 13 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 98,937 | $177K |
| 14 | WealthShield Partners, LLC | 91,530 | $164K |
| 15 | IEQ CAPITAL, LLC | 81,316 | $146K |